Abstract
Small interfering RNAs (siRNA) are one of the most recent additions used to silence gene expression. At present, siRNA is the most extensively used gene-silencing technique over other nucleic-acid based approaches to treat diseases including cancer, hepatitis, respiratory disease, cardiovascular diseases, neuronal disease and autoimmune disease. However, systemic delivery of siRNA remains to be the biggest challenge to be overcome. Various strategies have been developed to deliver siRNA efficiently into target cell such as chemical modification of siRNA, physical strategies, viral and non viral-vectors mediated delivery. Among all the approaches non viral vectors including lipoplexes, polyplexes and inorganic nanoparticles were found to be most successful which have been reviewed in this article. Further therapeutic applications of RNAi have also been briefly reviewed.
Keywords: siRNA, Gene Silencing, viral vector, non-viral vector, polymeric systems
Current Gene Therapy
Title: siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Volume: 10 Issue: 2
Author(s): Bharat Khurana, Amit K. Goyal, Abhishek Budhiraja, Daisy Arora and Suresh P. Vyas
Affiliation:
Keywords: siRNA, Gene Silencing, viral vector, non-viral vector, polymeric systems
Abstract: Small interfering RNAs (siRNA) are one of the most recent additions used to silence gene expression. At present, siRNA is the most extensively used gene-silencing technique over other nucleic-acid based approaches to treat diseases including cancer, hepatitis, respiratory disease, cardiovascular diseases, neuronal disease and autoimmune disease. However, systemic delivery of siRNA remains to be the biggest challenge to be overcome. Various strategies have been developed to deliver siRNA efficiently into target cell such as chemical modification of siRNA, physical strategies, viral and non viral-vectors mediated delivery. Among all the approaches non viral vectors including lipoplexes, polyplexes and inorganic nanoparticles were found to be most successful which have been reviewed in this article. Further therapeutic applications of RNAi have also been briefly reviewed.
Export Options
About this article
Cite this article as:
Khurana Bharat, K. Goyal Amit, Budhiraja Abhishek, Arora Daisy and P. Vyas Suresh, siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing, Current Gene Therapy 2010; 10 (2) . https://dx.doi.org/10.2174/156652310791111010
DOI https://dx.doi.org/10.2174/156652310791111010 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deaza Analogs of Folic Acid as Antitumor Agents
Current Pharmaceutical Design Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Medical and Societal Impact
Current Immunology Reviews (Discontinued) Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Biochemical Markers of Renal Function
Current Medicinal Chemistry PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Update on Pathogenesis of Sjogren's Syndrome
Current Rheumatology Reviews Molecular Characteristics of Autoimmune Pancreatitis
Current Pharmaceutical Design NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives
Current Drug Targets Control of Interleukin-1β Secretion in Inflammation and Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design Natural Killer T Cells as Targets for Therapeutic Intervention in Autoimmune Diseases
Current Pharmaceutical Design Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets Regulatory T Cell Therapy for Type I Diabetes Targeting on β Cell Associated Autoantigens
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)